Demyelinating disease
diseaseOn this page
Also known as demyelinating disorder
Summary
Demyelinating disease (MONDO:0002562) is a disease (an umbrella term covering 8 Mondo subtypes) and 27 clinical trials. Top therapeutic interventions include clemastine, ocrelizumab, and methotrexate. A subtype of neurodegenerative disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 8 Mondo subtypes
- Clinical trials: 27
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | demyelinating disease |
| Mondo ID | MONDO:0002562 |
| MeSH | D003711 |
| DOID | DOID:3213 |
| NCIT | C34527 |
| UMLS | C0011303 |
| MedGen | 4189 |
| Is cancer (heuristic) | no |
Also known as: demyelinating disorder
Disease family
This is a subtype of neurodegenerative disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › neurodegenerative disease › demyelinating disease
Related subtypes (21): synucleinopathy, eyelid degenerative disorder, senile degeneration of brain, olivopontocerebellar atrophy, neuroaxonal dystrophy, choroidal sclerosis, tauopathy, secondary Parkinson disease, infantile bilateral striatal necrosis, Marchiafava-Bignami disease, superficial siderosis, primary progressive apraxia of speech, human prion disease, primary progressive freezing gait, primary progressive aphasia, motor neuron disorder, brachial amyotrophic diplegia, cerebellar degeneration, inherited neurodegenerative disorder, cerebral degeneration, hypertrophic olivary degeneration
Subtypes (8): demyelinating polyneuropathy, central pontine myelinolysis, polyradiculoneuropathy, Schilder disease, Balo concentric sclerosis, acute disseminated encephalomyelitis, demyelinating disease of central nervous system, boylan dew greco syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Amiloride.
Clinical trials & evidence
Clinical trials
Clinical trials: 27.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 16 |
| PHASE1 | 4 |
| PHASE1/PHASE2 | 3 |
| PHASE4 | 1 |
| PHASE3 | 1 |
| PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00037115 | PHASE4 | WITHDRAWN | Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. |
| NCT05834855 | PHASE3 | RECRUITING | Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS |
| NCT06065670 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy |
| NCT00001287 | PHASE2 | COMPLETED | Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
| NCT01056471 | PHASE1/PHASE2 | COMPLETED | Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis |
| NCT04539002 | PHASE1/PHASE2 | COMPLETED | Aerobic Exercise for Remyelination in Multiple Sclerosis |
| NCT06999434 | PHASE1 | RECRUITING | Exploring the Utility of [18F]3F4AP for Demyelination Imaging |
| NCT00283023 | PHASE1 | COMPLETED | Oligodendrocyte Progenitor Cell Culture From Human Brain |
| NCT04710550 | PHASE1 | UNKNOWN | Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian Injury |
| NCT06677710 | PHASE1 | SUSPENDED | IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis |
| NCT06985303 | EARLY_PHASE1 | WITHDRAWN | Cell-Based Therapy for White Matter Repair in Periventricular Leukomalacia |
| NCT06494228 | Not specified | RECRUITING | Comparison of Diagnostic Performances of 3D FLAIR, DIR and PSIR Sequences in Optic Neuritis |
| NCT06534177 | Not specified | NOT_YET_RECRUITING | Digital Diagnostics and Intervention Services for Parkinson’s Disease |
| NCT06541626 | Not specified | RECRUITING | Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases |
| NCT06573723 | Not specified | RECRUITING | Institutional Registry of Rare Diseases |
| NCT00001780 | Not specified | COMPLETED | Magnetic Stimulation of the Human Nervous System |
| NCT01963650 | Not specified | TERMINATED | Natural History Study of Children With Metachromatic Leukodystrophy |
| NCT03010826 | Not specified | COMPLETED | Pharmacological Recruitment of Endogenous Neural Precursors to Promote Pediatric White Matter Repair: Establishing Correlations Between Visual Outcomes, Saccadic Function and MEG Oscillations in Children With Demyelinating Disorders in Comparison to Healthy Control Children |
| NCT03268239 | Not specified | COMPLETED | Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions |
| NCT03562975 | Not specified | COMPLETED | Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus |
| NCT04762342 | Not specified | UNKNOWN | Power Training in Older Multiple Sclerosis Patients |
| NCT04837651 | Not specified | COMPLETED | Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab |
| NCT04997343 | Not specified | UNKNOWN | Neurophysiological Assessment in Patients With Multiple Sclerosis |
| NCT05199363 | Not specified | UNKNOWN | Pediatric Patient Experience on a Diagnostic Path |
| NCT05605951 | Not specified | UNKNOWN | Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve |
| NCT05792176 | Not specified | COMPLETED | Ukulele Playing to Improve Cognition in People with Multiple Sclerosis: a Feasibility Study |
| NCT06019611 | Not specified | COMPLETED | Epidural Stimulation in Multiple Sclerosis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CLEMASTINE | 4 | 3 |
| OCRELIZUMAB | 4 | 2 |
| METHOTREXATE | 4 | 1 |
| METHYLPREDNISOLONE | 4 | 1 |
| INTERFERON BETA | 3 | 1 |
| CHEMBL426 | 0 | 1 |